A research team supported by the National Institutes of Health (NIH) has achieved a groundbreaking medical milestone by successfully delivering a personalized CRISPR-based gene editing therapy to treat an infant with carbamoyl phosphate synthetase 1 (CPS1) deficiency—a rare, life-threatening genetic liver disorder. This marks the first time a customized gene-editing therapy has been used in a human patient.